Clinical Trial

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study will evaluate the immune response of the RSVPreF3 OA investigational vaccine in Chinese adults 18 to 59 years of age (YOA) who are at increased risk of respiratory syncytial virus (RSV) disease, in comparison with the immune response generated in older adults 60 YOA and above from the 219815 (RSV OA=ADJ-021; NCT06551181) study following a single dose of the RSVPreF3 OA vaccine. In addition, the safety and reactogenicity of the vaccine will also be assessed.
Protocol Amendment History 3 changes
notable Primary completion pushed: 2026-07-16 -> 2026-09-25 2026-05-28
minor Completion pushed: 2026-12-14 -> 2027-03-12 2026-05-28
notable Trial sites expanded: 9 -> 13 locations 2026-04-21
Trial Details
NCT Number NCT07220109
Lead Sponsor GlaxoSmithKline
Conditions Respiratory Syncytial Virus Infections
Enrollment 750 participants
Start Date 2025-10-29
Primary Completion 2026-09-25 (estimated)
Study Completion 2027-03-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-27